4D Molecular Therapeutics Inc (FDMT) Stock Price, Quote & News

Company Profile

4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macu...

Industry: Biotechnology

Sector: Healthcare

Phone: 510 505 2680

Website: www.4dmoleculartherapeutics.com

Address:

5858 Horton Street, Suite 455, EmeryVille, United States

dixiebull Aug. 25 at 1:41 PM

$FDMT 16.50 incoming

0 · Reply

dixiebull Aug. 21 at 9:38 PM

$FDMT hit 16.91 this morning, stop under 12now

0 · Reply

dixiebull Aug. 19 at 6:00 PM

$FDMT tests 17 today

0 · Reply

dixiebull Aug. 18 at 1:53 PM

$FDMT got 15 yesterday, still more to go

0 · Reply

MikeCaymanTrades Aug. 18 at 1:20 AM

$FDMT - 17% daily chart moving from 9.50 to 14.31 Today wild action 12.25 to 15.00 with a big reversal after.

0 · Reply

StocktwitsNews Aug. 17 at 11:51 PM

OCUL, FDMT Stock Clock Best Day In Weeks After EyePoint’s Trial Setback — Here’s Why $OCUL $FDMT $EYPT https://stocktwits.com/news/equity/markets/ocul-fdmt-stock-clock-best-day-in-weeks-after-eye-point-s-trial-setback-here-s-why/cZYGkWURJS3

0 · Reply

Bullflagz Aug. 17 at 7:42 PM

$FDMT offering?

0 · Reply

notreload_ai Aug. 17 at 7:26 PM

$FDMT gains support as B. Riley views $EYPT Phase 3 setback as favorable for its lead gene therapy candidate 4D-150. https://notreload.xyz/xy/b-riley-keeps-buy-on-fdmt-after-eypt-miss/

0 · Reply

Merlintrader Aug. 17 at 4:52 PM

$EYPT, $OCUL, $FDMT, $RGNX: what LUGANO actually cost, and what it did not https://www.merlintrader.com/eypt-lugano-wet-amd-miss-2026/

0 · Reply

RunnerSignals Aug. 17 at 4:20 PM

$OABI $CLBK $MRK $CRDL $FDMT hit fresh 52-week highs. oabi runs on 23x volume, fdmt +22.1% on 1.5x

0 · Reply

4DMT to Participate in Upcoming Investor Conferences

2026-08-17T18:15:14.000Z - 20 days ago

B. Riley views EyePoint study miss as positive for 4D Molecular

EYPT

2026-08-16T14:01:58.000Z - 21 days ago

4D Molecular price target lowered to $32 from $33 at Goldman Sachs

Aug 14, 2026, 4:05 PM EDT - 23 days ago

4DMT Announces New Employment Inducement Grants

Aug 13, 2026, 4:05 PM EDT - 24 days ago

4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones

Aug 13, 2026, 7:00 AM EDT - 24 days ago

4D Molecular Therapeutics Quarterly report: Q2 2026

Aug 13, 2026, 7:00 AM EDT - 24 days ago

4D Molecular Therapeutics Earnings release: Q2 2026

2026-07-31T12:36:14.000Z - 5 weeks ago

4D Molecular initiated with a Buy at B. Riley

LLY

Jul 18, 2026, 3:15 PM EDT - 7 weeks ago

4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population

Jul 17, 2026, 7:00 AM EDT - 7 weeks ago

4D Molecular Therapeutics Slides: Corporate presentation

Jun 30, 2026, 4:05 PM EDT - 2 months ago

4DMT Announces Presentation at 44th Annual Scientific Meeting of the American Society of Retina Specialists

2026-06-29T12:15:46.000Z - 2 months ago

4D Molecular completes enrollment in 4FRONT-2 trial

Jun 29, 2026, 8:00 AM EDT - 2 months ago

4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules Capital

HTGC

Jun 29, 2026, 8:00 AM EDT - 2 months ago

4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMD

Jun 17, 2026, 1:30 PM EDT - 2 months ago

4D Molecular Therapeutics Transcript: AGM 2026

Jun 9, 2026, 2:00 PM EDT - 2 months ago

4D Molecular Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 3, 2026, 3:10 PM EDT - 3 months ago

4D Molecular Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

May 19, 2026, 2:35 PM EDT - 3 months ago

4D Molecular Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 13, 2026, 4:40 PM EDT - 3 months ago

4D Molecular Therapeutics Transcript: Bank of America Global Healthcare Conference 2026

2026-05-08T12:02:57.000Z - 4 months ago

4D Molecular price target lowered to $33 from $38 at Goldman Sachs

2026-05-07T22:48:23.000Z - 4 months ago

4D Molecular files $400M mixed securities shelf

May 7, 2026, 4:05 PM EDT - 4 months ago

4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones

May 7, 2026, 8:00 AM EDT - 4 months ago

4D Molecular Therapeutics Registration statement: Registration filing

May 7, 2026, 7:00 AM EDT - 4 months ago

4D Molecular Therapeutics Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 4 months ago

4D Molecular Therapeutics Earnings release: Q1 2026

May 7, 2026, 7:00 AM EDT - 4 months ago

4D Molecular Therapeutics Slides: Corporate presentation

Apr 28, 2026, 8:00 AM EDT - 4 months ago

4D Molecular Therapeutics Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 4 months ago

4D Molecular Therapeutics Proxy statement: Proxy filing

2026-04-13T13:56:19.000Z - 4 months ago

4D Molecular price target lowered to $23 from $45 at Evercore ISI

2026-03-30T13:08:58.000Z - 5 months ago

4D Molecular assumed with a Buy at Jefferies

Mar 18, 2026, 5:00 PM EDT - 5 months ago

4D Molecular Therapeutics Annual report: Q4 2025

Mar 18, 2026, 5:00 PM EDT - 5 months ago

4D Molecular Therapeutics Earnings release: Q4 2025

Mar 18, 2026, 4:05 PM EDT - 5 months ago

4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

Mar 18, 2026, 7:00 AM EDT - 5 months ago

4D Molecular Therapeutics Slides: Corporate presentation

Mar 16, 2026, 8:00 AM EDT - 5 months ago

4DMT to Participate in Upcoming Investor Meetings

Mar 12, 2026, 9:00 AM EDT - 5 months ago

4D Molecular Therapeutics Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 10, 2026, 4:20 PM EDT - 6 months ago

4D Molecular Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 3, 2026, 10:30 AM EST - 6 months ago

4D Molecular Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

2026-02-09T13:26:19.000Z - 6 months ago

4D Molecular completes enrollment for 4FRONT-1 Phase 3 trial

Feb 9, 2026, 8:00 AM EST - 6 months ago

4DMT Completes Enrollment for 4FRONT-1 Phase 3 Clinical Trial of 4D-150 in Wet AMD

2026-01-27T21:27:44.000Z - 7 months ago

4D Molecular assumed with an Overweight at Barclays

2026-01-19T18:35:06.000Z - 7 months ago

4D Molecular announces employment inducement grants

Jan 14, 2026, 10:30 AM EST - 7 months ago

4D Molecular Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 10:30 AM EST - 7 months ago

4D Molecular Therapeutics Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 7, 2026, 8:00 AM EST - 8 months ago

4DMT Provides Company Update and Anticipated Development Milestones for 2026

Dec 17, 2025, 8:00 AM EST - 8 months ago

4D Molecular Therapeutics Transcript: Study Result

Dec 17, 2025, 8:00 AM EST - 8 months ago

4D Molecular Therapeutics Press release: Study Result

Dec 17, 2025, 8:00 AM EST - 8 months ago

4D Molecular Therapeutics Slides: Study Result

2025-12-17T12:05:14.000Z - 8 months ago

4D Molecular announces interim data from 4D-710 Phase 1 AEROW trial

Dec 17, 2025, 7:00 AM EST - 8 months ago

4DMT Announces Positive Interim Clinical Data from 4D-710 AEROW Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease

Dec 8, 2025, 8:00 AM EST - 9 months ago

4DMT to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 3, 2025, 2:35 PM EST - 9 months ago

4D Molecular Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 20, 2025, 8:00 AM EST - 9 months ago

4DMT to Participate in 8th Annual Evercore Healthcare Conference

Nov 18, 2025, 4:00 AM EST - 9 months ago

4D Molecular Therapeutics Transcript: Jefferies London Healthcare Conference 2025

2025-11-17T11:10:33.000Z - 9 months ago

4D Molecular names Kristian Humer as CFO

Nov 17, 2025, 6:00 AM EST - 9 months ago

4DMT Appoints Kristian Humer as Chief Financial Officer

2025-11-11T14:25:18.000Z - 9 months ago

4D Molecular price target raised to $32 from $26 at RBC Capital

2025-11-11T10:25:26.000Z - 9 months ago

4D Molecular price target lowered to $33 from $38 at Barclays

Nov 10, 2025, 8:00 AM EST - 10 months ago

4DMT Reports Third Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

Nov 10, 2025, 8:00 AM EST - 10 months ago

4D Molecular Therapeutics Quarterly report: Q3 2025

Nov 10, 2025, 8:00 AM EST - 10 months ago

4D Molecular Therapeutics Earnings release: Q3 2025

Nov 6, 2025, 4:05 PM EST - 10 months ago

4DMT to Participate in Jefferies 2025 London Healthcare Conference

Nov 6, 2025, 6:23 AM EST - 10 months ago

4DMT Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants

Nov 6, 2025, 6:00 AM EST - 10 months ago

4DMT Announces Positive Long-Term Data from Phase 1/2 PRISM Clinical Trial in Wet AMD Supporting 4D-150's Potential as a Backbone Therapy with Consistent and Durable Benefit over Multiple Years

Oct 30, 2025, 11:02 PM EDT - 10 months ago

4DMT Announces Exclusive License Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of 4D-150 in Asia-Pacific

Oct 21, 2025, 2:00 PM EDT - 10 months ago

4D Molecular Therapeutics Transcript: Chardan’s 9th Annual Genetic Medicines Conference

Oct 21, 2025, 9:30 AM EDT - 10 months ago

4D Molecular Therapeutics Transcript: Chardan’s 9th Annual Genetic Medicines Conference

Oct 14, 2025, 8:00 AM EDT - 10 months ago

4DMT to Participate in Chardan's 9th Annual Genetic Medicines Conference

Oct 13, 2025, 8:00 AM EDT - 10 months ago

4DMT Advances 4D-710 to Phase 2 with Additional Funding and Support from the Cystic Fibrosis Foundation

Sep 9, 2025, 1:50 PM EDT - 12 months ago

4D Molecular Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 9, 2025, 10:00 AM EDT - 12 months ago

4D Molecular Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 11:30 AM EDT - 1 year ago

4D Molecular Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Sep 2, 2025, 8:00 AM EDT - 1 year ago

4DMT Announces Leadership Expansion with Proven Late-Stage Executives to Drive 4D-150 Execution and BLA Readiness

Aug 13, 2025, 2:30 PM EDT - 1 year ago

4D Molecular Therapeutics Transcript: H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Aug 11, 2025, 8:00 AM EDT - 1 year ago

4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

Aug 11, 2025, 8:00 AM EDT - 1 year ago

4D Molecular Therapeutics Quarterly report: Q2 2025

Aug 11, 2025, 8:00 AM EDT - 1 year ago

4D Molecular Therapeutics Earnings release: Q2 2025

Aug 6, 2025, 8:00 AM EDT - 1 year ago

4DMT to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Jul 31, 2025, 4:05 PM EDT - 1 year ago

4DMT Presents Positive 60-Week Results from 4D-150 SPECTRA Clinical Trial in DME and Regulatory Update

Jul 24, 2025, 8:00 AM EDT - 1 year ago

4DMT Announces Presentations at 43rd Annual Scientific Meeting of the American Society of Retina Specialists

Jul 2, 2025, 4:05 PM EDT - 1 year ago

4DMT Announces Accelerated 4D-150 Phase 3 Development in Wet AMD and Streamlined Organization to Drive Late-Stage Execution

Jun 11, 2025, 11:20 AM EDT - 1 year ago

4D Molecular Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 11, 2025, 11:20 AM EDT - 1 year ago

4D Molecular Therapeutics Slides: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 4, 2025, 3:45 PM EDT - 1 year ago

4D Molecular Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Jun 4, 2025, 3:45 PM EDT - 1 year ago

4D Molecular Therapeutics Slides: FY 2025

May 14, 2025, 5:20 PM EDT - 1 year ago

4D Molecular Therapeutics Transcript: BofA Securities 2025 Healthcare Conference

May 14, 2025, 5:20 PM EDT - 1 year ago

4D Molecular Therapeutics Slides: FY 2025

May 8, 2025, 4:05 PM EDT - 1 year ago

4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

May 8, 2025, 4:00 PM EDT - 1 year ago

4D Molecular Therapeutics Earnings release: Q1 2025

May 8, 2025, 4:00 PM EDT - 1 year ago

4D Molecular Therapeutics Quarterly report: Q1 2025

May 1, 2025, 8:00 AM EDT - 1 year ago

4DMT Announces RMAT Designation Granted by FDA for 4D-150 for DME

Apr 29, 2025, 8:00 AM EDT - 1 year ago

4D Molecular Therapeutics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

4D Molecular Therapeutics Proxy statement: Proxy Filing

Apr 3, 2025, 9:15 AM EDT - 1 year ago

4D Molecular Therapeutics Transcript: RBC Inaugural Virtual Ophthalmology Conference

Apr 3, 2025, 9:15 AM EDT - 1 year ago

4D Molecular Therapeutics Slides: RBC Inaugural Virtual Ophthalmology Conference

Mar 12, 2025, 10:00 AM EDT - 1 year ago

4D Molecular Therapeutics Transcript: Barclays 27th Annual Global Healthcare Conference

Mar 12, 2025, 10:00 AM EDT - 1 year ago

4D Molecular Therapeutics Slides: Barclays 27th Annual Global Healthcare Conference

Mar 11, 2025, 10:00 AM EDT - 1 year ago

4D Molecular Therapeutics Transcript: Leerink Global Healthcare Conference 2025

Mar 11, 2025, 10:00 AM EDT - 1 year ago

4D Molecular Therapeutics Slides: FY 2025

Mar 10, 2025, 8:00 AM EDT - 1 year ago

4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD

Feb 28, 2025, 4:05 PM EST - 1 year ago

4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones

Feb 28, 2025, 4:00 PM EST - 1 year ago

4D Molecular Therapeutics Annual report: Q4 2024

Feb 28, 2025, 4:00 PM EST - 1 year ago

4D Molecular Therapeutics Earnings release: Q4 2024

Feb 10, 2025, 8:00 AM EST - 1 year ago

4D Molecular Therapeutics Transcript: Study Result

Feb 10, 2025, 8:00 AM EST - 1 year ago

4D Molecular Therapeutics Press release: Study Result

Feb 10, 2025, 8:00 AM EST - 1 year ago

4D Molecular Therapeutics Slides: Study Result

Feb 8, 2025, 2:30 PM EST - 1 year ago

4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program

Dec 3, 2024, 1:45 PM EST - 1 year ago

4D Molecular Therapeutics Transcript: 7th Annual Evercore ISI HealthCONx Conference

Nov 19, 2024, 7:00 AM EST - 1 year ago

4D Molecular Therapeutics Transcript: Jefferies London Healthcare Conference 2024

Nov 19, 2024, 7:00 AM EST - 1 year ago

4D Molecular Therapeutics Slides: FY 2024

Nov 13, 2024, 4:05 PM EST - 1 year ago

4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones

dixiebull Aug. 25 at 1:41 PM

$FDMT 16.50 incoming

0 · Reply

dixiebull Aug. 21 at 9:38 PM

$FDMT hit 16.91 this morning, stop under 12now

0 · Reply

dixiebull Aug. 19 at 6:00 PM

$FDMT tests 17 today

0 · Reply

dixiebull Aug. 18 at 1:53 PM

$FDMT got 15 yesterday, still more to go

0 · Reply

MikeCaymanTrades Aug. 18 at 1:20 AM

$FDMT - 17% daily chart moving from 9.50 to 14.31 Today wild action 12.25 to 15.00 with a big reversal after.

0 · Reply

StocktwitsNews Aug. 17 at 11:51 PM

0 · Reply

Bullflagz Aug. 17 at 7:42 PM

$FDMT offering?

0 · Reply

notreload_ai Aug. 17 at 7:26 PM

$FDMT gains support as B. Riley views $EYPT Phase 3 setback as favorable for its lead gene therapy candidate 4D-150. https://notreload.xyz/xy/b-riley-keeps-buy-on-fdmt-after-eypt-miss/

0 · Reply

Merlintrader Aug. 17 at 4:52 PM

$EYPT, $OCUL, $FDMT, $RGNX: what LUGANO actually cost, and what it did not https://www.merlintrader.com/eypt-lugano-wet-amd-miss-2026/

0 · Reply

RunnerSignals Aug. 17 at 4:20 PM

$OABI $CLBK $MRK $CRDL $FDMT hit fresh 52-week highs. oabi runs on 23x volume, fdmt +22.1% on 1.5x

0 · Reply

Tea_n_crumpet_enjoyer Aug. 17 at 3:43 PM

$FDMT if anyone’s wondering why this is up so much …. $EYPT missed primary endpoint

1 · Reply

mullymt Aug. 17 at 3:28 PM

$FDMT Did some sort of news come out? Because WOW.

0 · Reply

BioRich Aug. 17 at 2:10 PM

$FDMT Hope y'all haven't been sleeping on this gem. Had been stagnant for so long and now appears unstoppable. No sign of slowing down anytime soon. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!

1 · Reply

szeebs Aug. 17 at 3:51 AM

$FDMT

1 · Reply

Tea_n_crumpet_enjoyer Aug. 14 at 8:05 PM

$FDMT Been a while since I been in here … seems a lot has changed and I’m not going to get my 7 or 8 $ re entry before phase 3 readouts. Annoying

0 · Reply

Helpmrwizard Aug. 14 at 7:58 PM

$MGTX and $FDMT both coming on strong today, despite a lackluster $XBI

1 · Reply

Merlintrader Aug. 13 at 6:01 PM

Wet AMD durability race 2026: $OCUL, $EYPT, $RGNX, $FDMT and the readouts that settle it https://www.merlintrader.com/wet-amd-durability-race-2026/

1 · Reply

McMillion1 Aug. 13 at 1:08 AM

$FDMT 142% ⬆️ exit

1 · Reply

BioRich Aug. 12 at 6:17 AM

$FDMT continues to move higher

0 · Reply

McMillion1 Aug. 6 at 12:36 PM

$IOVA Market open will send this to 40%-50% up… $FDMT $VIR $GOSS $FBLG

0 · Reply

Quantumup Jul. 31 at 2:48 PM

BRiley🏁 $FDMT and said -- We are initiating coverage of retinal genetic medicines specialist 4D Molecular Therapeutics, Inc. (FDMT) with a Buy rating and a 12-month price target of $37/share. OCUL EYPT $RGNX - $ABBV $REGN $RHHBY SRZN KOD OTLK NVS Here's what else BRiley had to say in its initiation report: https://x.com/Quantumup1/status/2083203038202692017?s=20

0 · Reply

notreload_ai Jul. 31 at 1:30 PM

$FDMT gene therapy could reduce eye injections for AMD patients. B. Riley sees major upside if Phase 3 results succeed. 4D-150 gene therapy fully funded to H2 2028. https://notreload.xyz/xy/b-riley-initiates-fdmt-buy-37-pt/

0 · Reply

Market Cap	827.00M
Revenue (ttm)	85.21M
Net Income (ttm)	-140.11M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-164.43%
Debt to Equity Ratio	0.05

Volume	420,600
Avg Vol	942,210
Day's Range	N/A - N/A
Shares Out	55.24M
Stochastic %K	49%
Beta	2.74
Analysts	Strong Sell
Price Target	$29.10